Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

21. Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines

Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Last updated: May (...) 11, 2018 Project Number: RB1217-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of non-pharmacological or alternative interventions compared to proton pump inhibitors for patients with disorders of excessive acid secretion? What are the evidence-based guidelines for non-pharmacological or alternative interventions for patient with excessive acid secretion? Key Message One non

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Full Text available with Trip Pro

A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME). This study aimed to investigate whether OME can be effectively treated with a proton pump inhibitor (PPI), therefore implicating GER as a causative factor of OME.A PPI or placebo was randomly administered to enrolled subjects for 4-8 weeks. To monitor effusion status, subjects underwent monthly pneumatic

2018 The journal of international advanced otology Controlled trial quality: uncertain

23. Pneumonia caused by proton pump inhibitors (PPI)

ATPase regulates surfactant secretion in rat alveolar type II cells by modulating lamellar body calcium. PLoS One. 2010 Feb 16;5(2):e9228. PMID:20169059 13) Bidani A, et al. Bactericidal activity of alveolar macrophages is suppressed by V-ATPase inhibition. Lung. 2000;178(2):91-104. PMID: 10773135Page 42 · MED CHECK - TIP December 2017/ Vol.3 No.9 Pneumonia caused by proton pump inhibitor (PPI): Translated from MedCheckTIP in Japanese Mov 2017 : 17(74):131-132 (2) Critical appraisal of a study using (...) Pneumonia caused by proton pump inhibitors (PPI) MED CHECK - TIP December 2017 / Vol.3 No.9 · Page 27 -The Informed Prescriber C N o 9 M ED HECK D e ce m b e r 2 0 1 7 WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia, Sleep Duration, Harm of hypnotics PPI causes Pneumonia Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than

2018 Med Check - The Informed Prescriber

24. Cough: Proton pump inhibitors

Cough: Proton pump inhibitors Proton pump inhibitors | Prescribing information | Cough | CKS | NICE Search CKS… Menu Proton pump inhibitors Cough: Proton pump inhibitors Last revised in April 2020 Proton pump inhibitors For detailed information on prescribing a proton pump inhibitor, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

25. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Full Text available with Trip Pro

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.This study was based on a territory-wide health database of Hong Kong. We identified adults who

2017 EvidenceUpdates

26. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Full Text available with Trip Pro

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored.We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study

2017 Kidney international reports

27. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial (Abstract)

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard

2017 EvidenceUpdates

28. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Full Text available with Trip Pro

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance-associated

2017 Hepatology communications

29. Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Full Text available with Trip Pro

Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Background and Aims: Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected (...) patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association. Methods: Comprehensive literature review was conducted by first searching the Medline and Embase databases through March 2017 to identify all studies that investigated the safety and efficacy of DAAs in patients with HCV infection taking PPIs versus those without PPIs. Adjusted point

2017 Journal of clinical and translational hepatology

30. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease Full Text available with Trip Pro

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD).A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case

2017 EvidenceUpdates

31. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience Full Text available with Trip Pro

Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center.We evaluated the medical records of all patients admitted to the University Hospital of Tübingen, Germany, for treatment of PUD during 1989-2008. Patients were included into the study if the diagnosis was verified endoscopically or surgically (...) . Annual number of admissions, length of hospitalization, mortality rate, age, rate of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitor (PPI) medication, rate of Helicobacter pylori infection, and complications of PUD and surgery performed were recorded. Data were analyzed by descriptive analyses, Pearson's chi-square test, and regression analysis.This study included 614 admissions. The number of annual admissions (31 ± 12), the length of hospitalization (9 ± 3 days

2017 Visceral medicine

32. Deprescribing proton pump inhibitors

Deprescribing proton pump inhibitors 354 Canadian Family Physician • Le Médecin de famille canadien | Vol 63: may • mai 2017 Clinical Practice Guidelines Deprescribing proton pump inhibitors Evidence-based clinical practice guideline Barbara Farrell PharmD ACPR FCSHP Kevin Pottie MD CCFP MClSc FCFP Wade Thompson Taline Boghossian ACPR Lisa Pizzola MSc Farah Joy Rashid ACPR Carlos Rojas-Fernandez PharmD Kate Walsh ACPR Vivian Welch PhD Paul Moayyedi MB ChB PhD MPH Abstract Objective To develop (...) an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process

2017 CPG Infobase

33. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Full Text available with Trip Pro

Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppress gastric acid production, which can inhibit iron absorption. However, few data exist regarding whether these medications increase the risk of clinical iron deficiency.A community-based case-control study evaluated the association between acid-suppressing medication use and the subsequent risk of iron deficiency. It contrasted 77,046 (...) day for at least 10 years (odds ratio, 4.27; 95% CI, 2.53-7.21). No similar strong associations were found for other commonly used prescription medications.Among patients without known risk factors for iron deficiency, gastric acid inhibitor use for ≥2 years was associated with an increased subsequent risk of iron deficiency. The risk increased with increasing potency of acid inhibition and decreased after medication discontinuation.Copyright © 2017 AGA Institute. Published by Elsevier Inc. All

2017 EvidenceUpdates

34. Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety

Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) with clopidogrel antiplatelet

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

35. [Optimal long-term use of proton pump inhibitors]

[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training

2017 Health Technology Assessment (HTA) Database.

36. Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Full Text available with Trip Pro

Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Widely regarded as safe and effective, proton pump inhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute

2017 Kidney international reports

37. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized

2017 Tools for Practice

38. Dyspepsia - proven peptic ulcer: Proton pump inhibitors

Dyspepsia - proven peptic ulcer: Proton pump inhibitors Proton pump inhibitors | Prescribing information | Dyspepsia - proven peptic ulcer | CKS | NICE Search CKS… Menu Proton pump inhibitors Dyspepsia - proven peptic ulcer: Proton pump inhibitors Last revised in October 2019 Proton pump inhibitors Choice of proton pump inhibitor Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with dyspepsia symptoms. Table 1 . PPI doses for the management (...) before the evening meal, to provide optimal control of gastric pH. * Off-label dose for GORD. † This is lower than the licensed starting dose in GORD, but is considered to be dose-equivalent to other PPIs. ‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg. Data from: [ ] Contraindications and cautions Proton pump inhibitors (PPIs) should not be prescribed to people: With alarm symptoms before endoscopy, as PPIs may

2017 NICE Clinical Knowledge Summaries

39. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Full Text available with Trip Pro

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually

2016 BMJ

40. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

2016 Therapeutics Letter